【ChiCTR2100048830】Antonello NICOLINI: please submit an approval letter of IRB Do not forget the lungs: I/E mode physiotherapy for people recovering from COVID-19. Preliminary feasibility
ChiCTR2100048830
结束
/
/
/
2021-07-18
/
/
post covid 19 syndrome
Antonello NICOLINI: please submit an approval letter of IRB Do not forget the lungs: I/E mode physiotherapy for people recovering from COVID-19. Preliminary feasibility
Do not forget the lungs: I/E mode physiotherapy for people recovering from COVID-19. Preliminary feasibility study
16039
evaluation of respiratory function parameters quality of life scores exercise capacity befora and after teatment with T-PEP 4 in patients with post COVID 19 syndrome
单臂
回顾性研究
na
/
no founding sources
/
20
/
2021-01-18
2021-07-01
/
1. Aged >=18 years 2. Discharged from hospital after a COVID19 pneumonia 3. In spontaneous breathing 4. Able to breathe keeping a mouthpiece 5. Mild to moderate obstructive syndrome at spirometry (12) and at least one symptom among: (1) Breathlessness or feeling as “I can't take a deep breath” or inability to yawn (2) Cough (3) Chest pain/Chest tightness (4) Dyspnoea (at rest or during normal ADL) (5) Oxygen desaturation >=4% during daily physical activities；
请登录查看Already on treatment with NIV or CPAP before COVID 19 - Oxygen supplementation at rest - Inability or refusal to collaborate - Lack of informed consent - Severe obstructive syndrome ( forced expiratory volume 1 second - FEV1 - < 50% )；
请登录查看asl4 chiavarese chiavari
/
asl4 chiavarese chiavari的其他临床试验
意大利Genoa sestri levante的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04